Sugi Predict

Sugi Predict / Compounds / SCHEMBL342059

SCHEMBL342059

SCHEMBL342059

N[C@H](C(=O)O)C1CCC(O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 4/20 0.46
▸ DPP7 Q9UHL4 3/20 0.46
▸ DPP8 Q6V1X1 1/20 0.46
▸ DPP9 Q86TI2 1/20 0.46
▸ SLC1A2 P43004 3/20 0.43
▸ SLC1A1 P43005 2/20 0.43
▸ GRM2 Q14416 3/20 0.40
▸ GRM3 Q14832 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ GRM8 O00222 1/20 0.40
▸ GRM6 O15303 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ APEX1 P27695 1/20 0.40
▸ GRM5 P41594 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ GRM1 Q13255 1/20 0.40
▸ GRM4 Q14833 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077492 1.00 DPP4 (0.46) DPP4DPP7DPP8DPP9SLC1A2
SCHEMBL650638 1.00 DPP4 (0.46) DPP4DPP7DPP8DPP9SLC1A2
SCHEMBL412802 0.90 — —
SCHEMBL412803 0.90 — —
SCHEMBL1531463 0.90 — —
Hydrochloric Acid SCHEMBL17423093 0.87 — —
Hydrochloric Acid SCHEMBL17423095 0.87 — —
SCHEMBL1764006 0.81 DPP4 (0.47) DPP4SLC1A2SLC1A1GRM2GRM3
SCHEMBL17729296 0.81 DPP4 (0.47) DPP4SLC1A2SLC1A1GRM2GRM3
SCHEMBL15190184 0.81 DPP4 (0.46) DPP4DPP7DPP8DPP9SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116856216-A Pavement shear stress structure and construction method 宁波市建设集团股份有限公司 2023-10-10 — — CN disclosed
CN-115094423-B Inorganic membrane removing liquid suitable for aluminum substrate circuit board and application thereof 深圳市板明科技股份有限公司 2022-11-08 — — CN disclosed
CN-115094423-A Inorganic film removing liquid suitable for aluminum substrate circuit board and application thereof 深圳市板明科技股份有限公司 2022-09-23 — — CN disclosed
US-9040706-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2015-05-26 — — US disclosed
US-8980837-B2 Inhibitors of IAP GENENTECH, INC. (US) 2015-03-17 — — US disclosed
US-8907092-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-12-09 — — US disclosed
EP-1778718-B1 INHIBITORS OF IAP GENENTECH INC (US) 2014-10-08 — — EP disclosed
US-8835393-B2 Inhibitors of IAP GENENTECH, INC. (US) 2014-09-16 — — US disclosed
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2014-03-20 — — US disclosed
US-8609845-B2 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2013-12-17 — — US disclosed
US-20070299052-A1 Inhibitors of IAP GENENTECH, INC. (US) 2007-12-27 — — US disclosed
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof SMITHKLINE BEECHAM CORPORATION (US) 2007-10-25 — — US disclosed
EP-1836201-A1 PYRROLIDINE INHIBITORS OF IAP Genentech, Inc. (US) 2007-09-26 — — EP disclosed
WO-2007106192-A2 INHIBITORS OF IAP GENENTECH, INC. (US) 2007-09-20 — — WO disclosed
US-7244851-B2 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2007-07-17 — — US disclosed
EP-1778718-A1 INHIBITORS OF IAP Genentech, Inc. (US) 2007-05-02 — — EP disclosed
US-20060167066-A1 Pyrrolidine inhibitors of IAP GENENTECH, INC. (US) 2006-07-27 — — US disclosed
WO-2006069063-A1 PYRROLIDINE INHIBITORS OF IAP GENENTECH, INC. (US) 2006-06-29 — — WO disclosed
WO-2006014361-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2006-02-09 — — WO disclosed
US-20060014700-A1 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249670-A1 Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof PYGM, PYGL, GYS1 DPP4 38/4885DPP7 98/4885DPP8 118/4885
US-20070299052-A1 Inhibitors of IAP XIAP, BIRC5, BIRC3 DPP4 1206/4885DPP7 922/4885DPP8 934/4885
US-20060167066-A1 Pyrrolidine inhibitors of IAP BIRC5, XIAP, BIRC2 DPP4 1280/4885DPP7 970/4885DPP8 1464/4885
US-20140080805-A1 PYRROLIDINE INHIBITORS OF IAP BIRC5, XIAP, BIRC2 DPP4 1205/4885DPP7 920/4885DPP8 1395/4885
US-20060014700-A1 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies BIRC5, BIRC2, XIAP DPP4 1366/4885DPP7 476/4885DPP8 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.